pharmaphorum

JULY 14, 2021

The shot also includes two “conserved” pneumococcal proteins – antigens that seem always to be present in the bacterium regardless of its serotype, so could potentially provide protection against an even broader range. The post Shot in the arm for Affinivax as it challenges Pfizer’s Prevnar appeared first on.

Immune Response 52

Immune Response Vaccination Vaccine Protein 52

XTalks

NOVEMBER 10, 2020

Interim results of the trial show that all participants developed an antibody response after two doses of the COVID-19 adjuvanted vaccine candidate. We also observed that the antibody levels were higher after vaccination than those observed in convalescent sera from people who recovered from the disease,” said Landry.

Vaccination 52

Vaccination Vaccine Trials Immune Response 52

pharmaphorum

MAY 31, 2022

billion in potential development milestones, to get its hands on the ASP3772 shot, which recently claimed a breakthrough designation from the FDA for the treatment of pneumococcal disease in older adults. The biotech says this can stimulate both B cell (antibody) and T cell immune responses with a single shot.

Vaccination 52

Vaccination Vaccine Bacterium Sales 52

The Pharma Data

MAY 31, 2022

billion in potential development milestones Proposed acquisition provides access to next-generation 24-valent pneumococcal vaccine candidate in phase II development and highly innovative, MAPS TM technology Supports development of a strong portfolio of innovative vaccines and specialty medicines. GSK to pay $2.1

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

The Pharma Data

JUNE 2, 2022

billion in potential development milestones. Affinivax is pioneering the development of a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines. A 30-plus valent pneumococcal candidate vaccine is also in pre-clinical development. billion upfront payment and up to $1.2

Vaccination 52

Vaccination Vaccine Immune Response Protein 52